ADC Therapeutics is focused on the development of proprietary antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers.
Route de la Corniche 3B, 1066 Epalinges, Switzerland
Cell Receptor Inc. has IP for improving results in oncological treatment by targeting upstream steps of growth signaling, not noticed in oncology yet. A well-tolerated affordable treatment of low toxicity! It will prevent metastasis in most cancers.www.nature.com/articles/d43747-021-00133-8